Engineered immune cells take on tough leukemia in new trial
Disease control
Ongoing
This study tests a treatment called AUTO1, a type of CAR T cell therapy, in 153 adults whose B cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attac…
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC